{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T06:14:08Z","timestamp":1648620848098},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:00:00Z","timestamp":1477872000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00393-016-0217-9","type":"journal-article","created":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T08:51:56Z","timestamp":1477903916000},"page":"956-963","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Einsatz von Immunglobulinen"],"prefix":"10.1007","volume":"75","author":[{"given":"T.","family":"Witte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,31]]},"reference":[{"issue":"Suppl 1","key":"217_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cei.1996.104.s1.10","volume":"104","author":"J Andersson","year":"1996","unstructured":"Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes\/macrophages. Clin Exp Immunol 104(Suppl 1):10\u201321","journal-title":"Clin Exp Immunol"},{"key":"217_CR2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","volume":"101","author":"J Bayry","year":"2003","unstructured":"Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV (2003) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101:758\u2013765","journal-title":"Blood"},{"key":"217_CR3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55:505\u2013509","journal-title":"Gut"},{"key":"217_CR4","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1002\/eji.201444700","volume":"44","author":"WA Carrock-Sewell","year":"2014","unstructured":"Carrock-Sewell WA, Kerr J, Behr-Gross ME, Peter HH (2014) European consensus proposal for immunoglobulin therapies. Eur J Immunol 44:2207\u20132214","journal-title":"Eur J Immunol"},{"key":"217_CR5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1177\/0961203314540764","volume":"23","author":"R Cervera","year":"2014","unstructured":"Cervera R, Rodr\u00edguez-Pint\u00f3 I, Espinosa G, Task Force on Catastrophic Antiphospholipid Syndrome (2014) Catastrophic antiphospholipid syndrome: task force report summary. Lupus 23:1283\u20131285","journal-title":"Lupus"},{"key":"217_CR6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"P Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, Eymard B, Herson S (2002) Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46:467\u2013474","journal-title":"Arthritis Rheum"},{"key":"217_CR7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.58.2.326","volume":"58","author":"P Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S, Eymard B (2002) Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58:326","journal-title":"Neurology"},{"key":"217_CR8","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1365-2133.2007.08217.x","volume":"157","author":"DL Cummins","year":"2007","unstructured":"Cummins DL, Anhalt GJ, Monahan T, Meyerle JH (2007) Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol 157:1235\u20131239","journal-title":"Br J Dermatol"},{"issue":"12 Suppl 6","key":"217_CR9","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1212\/WNL.59.12_suppl_6.S13","volume":"59","author":"MC Dalakas","year":"2002","unstructured":"Dalakas MC (2002) Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59(12 Suppl 6):S13\u2013S21","journal-title":"Neurology"},{"key":"217_CR10","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993\u20132000","journal-title":"N Engl J Med"},{"key":"217_CR11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"56","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56:323\u2013327","journal-title":"Neurology"},{"key":"217_CR12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48:712\u2013716","journal-title":"Neurology"},{"key":"217_CR13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","volume":"9","author":"MG Danieli","year":"2009","unstructured":"Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A (2009) Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 9:124\u2013127","journal-title":"Autoimmun Rev"},{"key":"217_CR14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","volume":"15","author":"I Elovaara","year":"2008","unstructured":"Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg S\u00f8rensen P, Udd B, EFNS (2008) EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 15:893\u2013908","journal-title":"Eur J Neurol"},{"key":"217_CR15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1684\/ejd.2008.0580","volume":"19","author":"A Enk","year":"2009","unstructured":"Enk A, European Dermatology Forum Guideline Subcommittee (2009) Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 19:90\u201398","journal-title":"Eur J Dermatol"},{"key":"217_CR16","first-page":"CD007057","volume":"1","author":"PM Fortin","year":"2013","unstructured":"Fortin PM, Tejani AM, Bassett K, Musini VM (2013) Intravenous immunoglobulin as adjuvant therapy for Wegener\u2019s granulomatosis. Cochrane Database Syst Rev 1:CD007057","journal-title":"Cochrane Database Syst Rev"},{"key":"217_CR17","unstructured":"Department of Health. Clinical Guidelines for Immunoglobulin Use. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/216671\/dh_131107.pdf . Zugegriffen: 25.10.2016"},{"key":"217_CR18","unstructured":"Gemeinsamer Bundesausschuss. Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittelrichtlinie (AM-RL): Anlage VI - Off-Label-Use Intraven\u00f6se Immunglobuline (IVIG) bei Polymyositis und bei Dermatomyositis. https:\/\/www.g-ba.de\/downloads\/39-261-1701\/2013-04-18_AM-RL-VI_OLU_IVIG-PM-DM_BAnz.pdf . Zugegriffen: 25.10.2016"},{"key":"217_CR19","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/rheumatology\/39.11.1301","volume":"39","author":"M Hundt","year":"2000","unstructured":"Hundt M, Manger K, D\u00f6rner T, Grimbacher B, Kalden P, Rascu A, Weber D, Burmester GR, Peter HH, Kalden JR, Schmidt RE (2000) Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford) 39:1301\u20131302","journal-title":"Rheumatology (Oxford)"},{"key":"217_CR20","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","volume":"1","author":"P Imbach","year":"1981","unstructured":"Imbach P, Barandun S, d\u2019Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Sch\u00f6ni M, Vest M, Wagner HP (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228\u20131231","journal-title":"Lancet"},{"key":"217_CR21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","volume":"93","author":"DR Jayne","year":"2000","unstructured":"Jayne DR, Chapel H, Adu D, Misbah S, O\u2019Donoghue D, Scott D, Lockwood CM (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433\u2013439","journal-title":"QJM"},{"key":"217_CR22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","volume":"345","author":"MD Kazatchkine","year":"2001","unstructured":"Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747\u2013755","journal-title":"N Engl J Med"},{"key":"217_CR23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3389\/fimmu.2014.00629","volume":"5","author":"J Kerr","year":"2014","unstructured":"Kerr J, Quinti I, Eibl M, Chapel H, Sp\u00e4th PJ, Carrock Sewell WA et al (2014) Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Front Immunol 5:629","journal-title":"Front Immunol"},{"key":"217_CR24","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1365-2133.2007.08433.x","volume":"158","author":"A Kreuter","year":"2008","unstructured":"Kreuter A, Reich-Schupke S, St\u00fccker M, St\u00fccker M, Altmeyer P, Gambichler T (2008) Intravenous immunoglobulin for pyoderma gangrenosum. Br J Dermatol 158:856\u2013857","journal-title":"Br J Dermatol"},{"key":"217_CR25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1191\/1352458504ms987cr","volume":"10","author":"N Kumar","year":"2004","unstructured":"Kumar N, Rodriguez M (2004) Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler 10:85\u201386","journal-title":"Mult Scler"},{"key":"217_CR26","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/rheumatology\/kem146a","volume":"46","author":"C Lapraik","year":"2007","unstructured":"Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D\u2019Cruz D, Guillevin L, Harper L, Jayne D, Luqmani R, Mooney J, Scott D, BSR and BHPR Standards, Guidelines and Audit Working Group (2007) BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology 46:1615\u20131616","journal-title":"Rheumatology"},{"key":"217_CR27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1191\/096120399678841007","volume":"8","author":"Y Levy","year":"1999","unstructured":"Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, Terryberry J, Meissner M, Lorber M, Peter JB, Shoenfeld Y (1999) A study of 20 SLE patients with intravenous immunoglobulin-clinical and serological response. Lupus 8:705\u2013712","journal-title":"Lupus"},{"key":"217_CR28","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/ard.2002.003996","volume":"62","author":"Y Levy","year":"2003","unstructured":"Levy Y, Uziel Y, Zandman GG, Amital H, Sherer Y, Langevitz P, Goldman B, Shoenfeld Y (2003) Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis 62:1221\u20131223","journal-title":"Ann Rheum Dis"},{"key":"217_CR29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1067\/mjd.2000.104001","volume":"43","author":"RK Lister","year":"2000","unstructured":"Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M, Rustin MH (2000) Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 43:403\u2013408","journal-title":"J Am Acad Dermatol"},{"key":"217_CR30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2003-05-1530","volume":"103","author":"HU Lutz","year":"2004","unstructured":"Lutz HU, Stammler P, Bianchi V, Tr\u00fceb RM, Hunziker T, Burger R, Jelezarova E, Sp\u00e4th PJ (2004) Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103:465\u2013472","journal-title":"Blood"},{"issue":"Suppl 3","key":"217_CR31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000290758","volume":"33","author":"A Matzdorff","year":"2010","unstructured":"Matzdorff A, Giagounidis A, Greinacher A, Hiller E, Kiefel V, M\u00fcller-Beissenhirtz H, Ostermann H, Rummel M, Sachs UJ, Salama A (2010) Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH. Onkologie 33(Suppl 3):2\u201320","journal-title":"Onkologie"},{"key":"217_CR32","unstructured":"http:\/\/www.med.umich.edu\/scleroderma\/pdf\/UCLA%20Questionnaire%20Translations%20Edited%2008-03-2015\/UCLA%20SCTC%20GIT%202.0_German_Switzerland_Final_11117_08-03-2015.pdf . Zugegriffen: 25-10-2016"},{"key":"217_CR33","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1093\/brain\/awh605","volume":"128","author":"K Mori","year":"2005","unstructured":"Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, Katsuno M, Fujita A, Aiba I, Ogata A, Saito T, Asakura K, Yoshida M, Hirayama M, Sobue G (2005) The wide spectrum of clinical manifestations in Sj\u00f6gren\u2019s syndrome-associated neuropathy. Brain 128:2518\u20132534","journal-title":"Brain"},{"key":"217_CR34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM198608073150601","volume":"315","author":"JW Newburger","year":"1986","unstructured":"Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP et\u00a0al (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341\u2013347","journal-title":"N Engl J Med"},{"key":"217_CR35","first-page":"CD004000","volume":"4","author":"RM Oates-Whitehead","year":"2003","unstructured":"Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS, Flynn I (2003) Intravenous immunoglobulin for the treatment of\u00a0Kawasaki\u00a0disease in children. Cochrane Database Syst Rev 4:CD004000","journal-title":"Cochrane Database Syst Rev"},{"key":"217_CR36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3899\/jrheum.140833","volume":"42","author":"CL Poelman","year":"2015","unstructured":"Poelman CL, Hummers LK, Wigley FM, Anderson C, Boin F, Shah AA (2015) Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J\u00a0Rheumatol 42:236\u2013242","journal-title":"J Rheumatol"},{"key":"217_CR37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","volume":"55","author":"J Raja","year":"2016","unstructured":"Raja J, Nihtyanova SI, Murray CD, Denton CP, Ong VH (2016) Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford) 55:115\u2013119","journal-title":"Rheumatology (Oxford)"},{"key":"217_CR38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.1995.tb02268.x","volume":"101","author":"C Richter","year":"1995","unstructured":"Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL (1995) Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 101:2\u20137","journal-title":"Clin Exp Immunol"},{"key":"217_CR39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A Samuelsson","year":"2001","unstructured":"Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484\u2013486","journal-title":"Science"},{"key":"217_CR40","first-page":"55","volume":"10","author":"Y Sherer","year":"2008","unstructured":"Sherer Y, Kuechler S, Jose Scali J, Rovensky J, Levy Y, Zandman-Goddard G, Shoenfeld Y (2008) Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 10:55\u201357","journal-title":"Isr Med Assoc J"},{"key":"217_CR41","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.43.5.876","volume":"43","author":"SA Soueidan","year":"1993","unstructured":"Soueidan SA, Dalakas MC (1993) Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 43:876\u2013879","journal-title":"Neurology"},{"key":"217_CR42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","volume":"187","author":"Y Suzuki","year":"2009","unstructured":"Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, Suda T, Chida K (2009) Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis. Lung 187:201\u2013206","journal-title":"Lung"},{"issue":"2 Suppl 76","key":"217_CR43","first-page":"151","volume":"31","author":"K Takehara","year":"2013","unstructured":"Takehara K, Ihn H, Sato S (2013) A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 31(2 Suppl 76):151\u2013156","journal-title":"Clin Exp Rheumatol"},{"key":"217_CR44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1081-1206(10)61714-0","volume":"92","author":"N Tsurikisawa","year":"2004","unstructured":"Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, Akiyama K (2004) Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 92:80\u201387","journal-title":"Ann Allergy Asthma Immunol"},{"key":"217_CR45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"MC Walter","year":"2000","unstructured":"Walter MC, Lochm\u00fcller H, Toepfer M, Schlotter B, Reilich P, Schr\u00f6der M, M\u00fcller-Felber W, Pongratz D (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247:22\u201328","journal-title":"J Neurol"},{"key":"217_CR46","volume-title":"S2k-Leitlinie Myositissyndrome","author":"H Wiendl","year":"2014","unstructured":"Wiendl H (2014) S2k-Leitlinie Myositissyndrome. http:\/\/www.awmf.org\/leitlinien\/detail\/ll\/030-054.html . Zugegriffen: 25.10.2016"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-016-0217-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-016-0217-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-016-0217-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T01:39:17Z","timestamp":1601170757000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-016-0217-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,31]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["217"],"URL":"https:\/\/doi.org\/10.1007\/s00393-016-0217-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,31]]}}}